206 related articles for article (PubMed ID: 37474439)
21. Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas.
Al-Harthy M; Al-Harthy S; Al-Otieschan A; Velagapudi S; Alzahrani AS
Endocr Pract; 2009 Apr; 15(3):194-202. PubMed ID: 19364686
[TBL] [Abstract][Full Text] [Related]
22. N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.
Leijon H; Kaprio T; Heiskanen A; Satomaa T; Hiltunen JO; Miettinen MM; Arola J; Haglund C
J Clin Endocrinol Metab; 2017 Nov; 102(11):3990-4000. PubMed ID: 28938401
[TBL] [Abstract][Full Text] [Related]
23. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
Stenman A; Zedenius J; Juhlin CC
Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
[TBL] [Abstract][Full Text] [Related]
24. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
[TBL] [Abstract][Full Text] [Related]
25. Morphologic Clues to Succinate Dehydrogenase (SDH) Deficiency in Pheochromocytomas and Paragangliomas.
Turchini J; Gill AJ
Am J Surg Pathol; 2020 Mar; 44(3):422-424. PubMed ID: 31789631
[No Abstract] [Full Text] [Related]
26. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
[TBL] [Abstract][Full Text] [Related]
27. Screening for pheochromocytomas and paragangliomas.
Eisenhofer G
Curr Hypertens Rep; 2012 Apr; 14(2):130-7. PubMed ID: 22258313
[TBL] [Abstract][Full Text] [Related]
28. Comparison of plasma metanephrines measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma.
Christensen TT; Frystyk J; Poulsen PL
Scand J Clin Lab Invest; 2011 Dec; 71(8):695-700. PubMed ID: 22023043
[TBL] [Abstract][Full Text] [Related]
29. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
[TBL] [Abstract][Full Text] [Related]
30. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.
Pamporaki C; Hamplova B; Peitzsch M; Prejbisz A; Beuschlein F; Timmers HJLM; Fassnacht M; Klink B; Lodish M; Stratakis CA; Huebner A; Fliedner S; Robledo M; Sinnott RO; Januszewicz A; Pacak K; Eisenhofer G
J Clin Endocrinol Metab; 2017 Apr; 102(4):1122-1132. PubMed ID: 28324046
[TBL] [Abstract][Full Text] [Related]
32. Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors.
März J; Kurlbaum M; Roche-Lancaster O; Deutschbein T; Peitzsch M; Prehn C; Weismann D; Robledo M; Adamski J; Fassnacht M; Kunz M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():722656. PubMed ID: 34557163
[TBL] [Abstract][Full Text] [Related]
33. Metastatic pheochromocytoma and paraganglioma.
Angelousi A; Kassi E; Zografos G; Kaltsas G
Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
[TBL] [Abstract][Full Text] [Related]
34. Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.
Zhong X; Ye L; Su T; Xie J; Zhou W; Jiang Y; Jiang L; Ning G; Wang W
Clin Endocrinol (Oxf); 2017 Aug; 87(2):127-135. PubMed ID: 28429830
[TBL] [Abstract][Full Text] [Related]
35. Pheochromocytomas and paragangliomas in humans and dogs.
Galac S; Korpershoek E
Vet Comp Oncol; 2017 Dec; 15(4):1158-1170. PubMed ID: 28120550
[TBL] [Abstract][Full Text] [Related]
36. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
[TBL] [Abstract][Full Text] [Related]
37. Pheochromocytoma and paraganglioma: imaging characteristics.
Baez JC; Jagannathan JP; Krajewski K; O'Regan K; Zukotynski K; Kulke M; Ramaiya NH
Cancer Imaging; 2012 May; 12(1):153-62. PubMed ID: 22571874
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma.
Rattenberry E; Vialard L; Yeung A; Bair H; McKay K; Jafri M; Canham N; Cole TR; Denes J; Hodgson SV; Irving R; Izatt L; Korbonits M; Kumar AV; Lalloo F; Morrison PJ; Woodward ER; Macdonald F; Wallis Y; Maher ER
J Clin Endocrinol Metab; 2013 Jul; 98(7):E1248-56. PubMed ID: 23666964
[TBL] [Abstract][Full Text] [Related]
39. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
40. Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy.
Liu L; Xie W; Song Z; Wang T; Li X; Gao Y; Li Y; Zhang J; Guo X
Clin Endocrinol (Oxf); 2022 Feb; 96(2):132-138. PubMed ID: 34486152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
